Citations 2
Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
Silverman, Lewis R. , Fenaux, Pierre , Al‐Kali, Aref , Baer, Maria R. , Scott, Bart L. , Greenberg, Peter L. , Kreuzer, Karl Anton, Collins, Robert H. , Azarnia, N., Garcia‐Manero, Guillermo , Sekeres, Mikkael A. , Roboz, Gail J. , Gaïdano, Gianluca , Platzbecker, Uwe , Steensma, David P. , Kreuzer, Karl‐Anton, Godley, Lucy A. , Atallah, Ehab
Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7092-7092
Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.
Fenaux, Pierre , Al‐Kali, Aref , Baer, Maria R. , Silverman, Lewis R. , Scott, Bart L. , Greenberg, Peter L. , Kreuzer, Karl Anton, Godley, Lucy A. , Collins, Robert H. , Azarnia, N., Garcia‐Manero, Guillermo , Godley, Lucy A , Sekeres, Mikkael A. , Roboz, Gail J. , Gaïdano, Gianluca , Platzbecker, Uwe , Steensma, David P. , Kreuzer, Karl‐Anton, Atallah, Ehab
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e18079-e18079